Dyne Therapeutics’ stock sees record rally, but one analyst says it could still climb a lot further, after a rival got bought ...

Dimitri Semenikhin, the retail trader behind the Beyond Meat stock rally is piling into a small biotech that recently pivoted ...

Despite its sharp rebound, the sector remains about 40% below its pandemic peak, leaving it as one of the few areas of the ...

To solve this critical challenge, he founded Nephrogen in 2022, a biotech startup that uses AI and advanced screening to ...

A well-crafted narrative helps investors see not just the molecule in front of them, but the broader therapeutic and ...

Editor’s Note: This deep dive was originally published Sept. 24, 2025, as a special edition of Biopharm Executive. Subscribe ...

Genmab A/S (NASDAQ: GMAB) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Ram Selvaraju ...

The University of California, Irvine has licensed a new cancer-fighting immunotherapy to biotech firm GlyTR Therapeutics Inc.

MapLight Therapeutics Inc. shares jumped as much as 23% after the biotechnology firm raised $258.9 million in an initial ...

The Swiss drugmaker on Sunday said it agreed to acquire U.S. biotech firm Avidity Biosciences for about $12 billion in cash ...

Biotech stocks have trailed the broader market this year, but more names are starting to show strength as the rally expands ...

The surge in biotech breeding has brought new scrutiny to how policies handle risk related to genetic manipulation. The ...